

# DRAFT landscape of COVID-19 candidate vaccines – 2 July 2020

18 candidate vaccines in clinical evaluation

| Platform                     | Type of candidate vaccine   | Developer   | Coronavirus target | Current stage of clinical evaluation/regulatory status-Coronavirus candidate   | Same platform for non-Coronavirus candidates         |
|------------------------------|---|---|--------------------|--|--|
| Non-Replicating Viral Vector | ChAdOx1-S   | University of Oxford/AstraZeneca                                  | SARS-CoV2          | Phase 3<br><a href="#">ISRCTN89951424</a><br>Phase 2b/3<br><a href="#">2020-001228-32</a><br>Phase 1/2<br><a href="#">PACTR202006922165132</a><br><a href="#">2020-001072-15</a> | MERS, influenza, TB, Chikungunya, Zika, MenB, plague |
| Non-Replicating Viral Vector | Adenovirus Type 5 Vector  | CanSino Biological Inc./Beijing Institute of Biotechnology        | SARS-CoV2          | Phase 2<br><a href="#">ChiCTR2000031781</a><br>Phase 1<br><a href="#">ChiCTR2000030906</a>   | Ebola  |
| RNA                          | LNP-encapsulated mRNA   | Moderna/NIAID   | SARS-CoV2          | Phase 2<br><a href="#">NCT04405076</a><br>Phase 1<br><a href="#">NCT04283461</a>   | multiple candidates                                  |
| DNA                          | DNA plasmid vaccine with electroporation  | Inovio Pharmaceuticals/International Vaccine Institute            | SARS-CoV2          | Phase 1/2<br><a href="#">NCT04447781</a><br><a href="#">NCT04336410</a>  | multiple candidates                                  |
| Inactivated                  | Inactivated   | Wuhan Institute of Biological Products/Sinopharm                  | SARS-CoV2          | Phase 1/2<br><a href="#">ChiCTR2000031809</a>  |  |
| Inactivated                  | Inactivated   | Beijing Institute of Biological Products/Sinopharm                | SARS-CoV2          | Phase 1/2<br><a href="#">ChiCTR2000032459</a>  |  |
| Inactivated                  | Inactivated + alum  | Sinovac   | SARS-CoV2          | Phase 1/2<br><a href="#">NCT04383574</a><br><a href="#">NCT04352608</a>  | SARS   |
| Protein Subunit              | Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M | Novavax   | SARS-CoV2          | Phase 1/2<br><a href="#">NCT04368988</a>   | RSV; CCHF, HPV, VZV, EBOV                            |
| RNA                          | 3 LNP-mRNAs   | BioNTech/Fosun Pharma/Pfizer                                      | SARS-CoV2          | Phase 1/2<br><a href="#">2020-001038-36</a><br><a href="#">NCT04368728</a>   |  |
| Inactivated                  | Inactivated   | Institute of Medical Biology, Chinese Academy of Medical Sciences | SARS-CoV2          | Phase 1<br><a href="#">NCT04412538</a>   |  |
| DNA                          | DNA Vaccine (GX-19)   | Genexine Consortium   | SARS-CoV2          | Phase 1<br><a href="#">NCT04445389</a>   |  |
| Non-Replicating Viral Vector | Adeno-based   | Gamaleya Research Institute                                       | SARS-CoV2          | Phase 1<br><a href="#">NCT04436471</a><br><a href="#">NCT04437875</a>  |  |
| Protein Subunit              | Native like Trimeric subunit Spike Protein vaccine  | Clover Biopharmaceuticals Inc./GSK/Dynavax                        | SARS-CoV2          | Phase 1<br><a href="#">NCT04405908</a>   | HIV, REV Influenza                                   |

**DISCLAIMER:**

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

|                 |  |  |           |   |   |
|-----------------|--|--|-----------|---|---|
| Protein Subunit | Adjuvanted recombinant protein (RBD-Dimer)     | Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences | SARS-CoV2 | Phase 1<br><a href="#">NCT04445194</a>      | MERS  |
| Protein Subunit | Recombinant spike protein with Advax™ adjuvant | Vaxine Pty Ltd/Medytox   | SARS-CoV2 | Phase 1<br><a href="#">NCT04453852</a>      |   |
| RNA             | LNP-nCoVsaRNA                                  | Imperial College London  | SARS-CoV2 | Phase 1<br><a href="#">ISRCTN17072692</a>   | EBOV; LASV, MARV, Inf (H7N9), RABV            |
| RNA             | mRNA   | Curevac  | SARS-CoV2 | Phase 1<br><a href="#">NCT04449276</a>      | RABV, LASV, YFV; MERS, InfA, ZIKV, DENV, NIPV |
| RNA             | mRNA   | People's Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech.                    | SARS-CoV2 | Phase 1<br><a href="#">ChiCTR2000034112</a> |   |

#### 129 candidate vaccines in preclinical evaluation

| Platform                     | Type of candidate vaccine                  | Developer  | Coronavirus target | Current stage of clinical evaluation/regulatory status- Coronavirus candidate | Same platform for non-Coronavirus candidates |
|------------------------------|--|--|--------------------|---|--|
| DNA                          | DNA plasmid vaccine S,S1,S2,RBD &N         | National Research Centre, Egypt                                      | SARS-CoV2          | Pre-Clinical  |  |
| DNA                          | DNA with electroporation                   | Karolinska Institute / Cobra Biologics (OPENCORONA Project)          | SARS-CoV2          | Pre-Clinical  |  |
| DNA                          | DNA with electroporation                   | Chula Vaccine Research Center  | SARS-CoV2          | Pre-Clinical  |  |
| DNA                          | DNA plasmid vaccine                        | Osaka University/ AnGes/ Takara Bio                                  | SARS-CoV2          | Pre-Clinical  |  |
| DNA                          | DNA  | Takis/Applied DNA Sciences/Evvivax                                   | SARS-CoV2          | Pre-Clinical  |  |
| DNA                          | Plasmid DNA, Needle-Free Delivery          | Immunomic Therapeutics, Inc./EpiVax, Inc./PharmaJet                  | SARS-CoV2          | Pre-Clinical  | SARS   |
| DNA                          | DNA plasmid vaccine                        | Zydus Cadila   | SARS-CoV2          | Pre-Clinical  |  |
| DNA                          | DNA vaccine                                | BioNet Asia  | SARS-CoV2          | Pre-Clinical  |  |
| DNA                          | DNA vaccine                                | University of Waterloo   | SARS-CoV2          | Pre-Clinical  |  |
| DNA                          | DNA vaccine                                | Entos Pharmaceuticals  | SARS-CoV2          | Pre-Clinical  |  |
| DNA                          | bacTRL-Spike                               | Symvivo  | SARS-CoV2          | Pre-Clinical  |  |
| Inactivated                  | Inactivated whole virus                    | National Research Centre, Egypt                                      | SARS-CoV2          | Pre-Clinical  |  |
| Inactivated                  | Inactivated                                | Beijing Minhai Biotechnology Co., Ltd.                               | SARS-CoV2          | Pre-Clinical  |  |
| Inactivated                  | TBD  | Osaka University/ BIKEN/ NIBIOHN                                     | SARS-CoV2          | Pre-Clinical  |  |
| Inactivated                  | Inactivated + CpG 1018                     | Sinovac/Dynavax  | SARS-CoV2          | Pre-Clinical  |  |
| Inactivated                  | Inactivated + CpG 1018                     | Valneva/Dynavax  | SARS-CoV2          | Pre-Clinical  |  |
| Inactivated                  | Inactivated                                | Research Institute for Biological Safety Problems, Rep of Kazakhstan | SARS-CoV2          | Pre-Clinical  |  |
| Live Attenuated Virus        | Codon deoptimized live attenuated vaccines | Codagenix/Serum Institute of India                                   | SARS-CoV2          | Pre-Clinical  | HAV, InfA, ZIKV, FMD, SIV, RSV, DENV         |
| Live Attenuated Virus        | Codon deoptimized live attenuated vaccines | Indian Immunologicals Ltd/Griffith University                        | SARS-CoV2          | Pre-Clinical  |  |
| Non-Replicating Viral Vector | Adeno-associated virus vector (AAVCOVID)   | Massachusetts Eye and Ear/Massachusetts General Hospital/AveXis      | SARS-CoV2          | Pre-Clinical  |  |

#### DISCLAIMER:

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

|                              |   |   |            |              |  |
|------------------------------|---|---|------------|--------------|--|
| Non-Replicating Viral Vector | MVA encoded VLP   | GeoVax/BravoVax   | SARS-CoV2  | Pre-Clinical | LASV, EBOV, MARV, HIV                        |
| Non-Replicating Viral Vector | Ad26  | Janssen Pharmaceutical Companies  | SARS-CoV2  | Pre-Clinical | Ebola, HIV, RSV                              |
| Non-Replicating Viral Vector | Replication defective Simian Adenovirus (GRAd) encoding SARS-CoV-2 S    | ReiThera/LEUKOCARE/Univercells  | SARS-CoV2  | Pre-Clinical |  |
| Non-replicating viral vector | MVA-S encoded   | DZIF – German Center for Infection Research/IDT Biologika GmbH                                      | SARS-CoV2  | Pre-clinical | Many   |
| Non-replicating viral vector | MVA-S   | IDIBAPS-Hospital Clinic, Spain  | SARS-CoV2  | Pre-clinical |  |
| Non-Replicating Viral Vector | adenovirus-based NasoVAX expressing SARS2-CoV spike protein             | Altimune  | SARS-CoV2  | Pre-Clinical | influenza                                    |
| Non-Replicating Viral Vector | [E1-, E2b-, E3-] hAd5-COVID19-Spike/Nucleocapsid                        | ImmunityBio, Inc. & NantKwest, Inc.   | SARS-CoV2  | Pre-Clinical | flu, Chik, Zika, EBOV, LASV, HIV/SIV, Cancer |
| Non-Replicating Viral Vector | Ad5 S (GREVAX™ platform)  | Greffex   | SARS-CoV2  | Pre-Clinical | MERS   |
| Non-Replicating Viral Vector | Oral Ad5 S  | Stabilitech Biopharma Ltd   | SARS-CoV2  | Pre-Clinical | Zika, VZV, HSV-2 and Norovirus               |
| Non-Replicating Viral Vector | adenovirus-based + HLA-matched peptides                                 | Valo Therapeutics Ltd   | Pan-Corona | Pre-Clinical |  |
| Non-Replicating Viral Vector | Oral Vaccine platform   | Vaxart  | SARS-CoV2  | Pre-Clinical | InfA, CHIKV, LASV, NORV; EBOV, RVF, HBV, VEE |
| Non-Replicating Viral Vector | MVA expressing structural proteins                                      | Centro Nacional Biotecnología (CNB-CSIC), Spain   | SARS-CoV2  | Pre-Clinical | Multiple candidates                          |
| Non-Replicating Viral Vector | Dendritic cell-based vaccine  | University of Manitoba  | SARS-CoV2  | Pre-Clinical |  |
| Non-Replicating Viral Vector | parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein | University of Georgia/University of Iowa  | SARS-CoV2  | Pre-Clinical | MERS   |
| Non-Replicating Viral Vector | Recombinant deactivated rabies virus containing S1                      | Bharat Biotech/Thomas Jefferson University  | SARS-CoV2  | Pre-Clinical | HeV, NiV, EBOV, LASSA, CCHFV, MERS           |
| Non-Replicating Viral Vector | Influenza A H1N1 vector   | National Research Centre, Egypt   | SARS-CoV2  | Pre-Clinical |  |
| Non-Replicating Viral Vector | Inactivated Flu-based SARS-CoV2 vaccine + Adjuvant                      | National Center for Genetic Engineering and Biotechnology (BIOTEC) /GPO, Thailand                   | SARS-CoV2  | Pre-Clinical |  |
| Protein Subunit              | Subunit   | Helix Biogen Consult, Ogbomoso & Trinity Immono-efficient Laboratory, Ogbomoso, Oyo State, Nigeria. | SARS-CoV2  | Pre-Clinical |  |
| Protein Subunit              | Protein Subunit S,N,M&S1 protein  | National Research Centre, Egypt   | SARS-CoV2  | Pre-Clinical |  |
| Protein Subunit              | Protein Subunit   | University of San Martin and CONICET, Argentina   | SARS-CoV2  | Pre-Clinical |  |
| Protein Subunit              | RBD protein fused with Fc of IgG + Adj.                                 | Chulalongkorn University/GPO, Thailand  | SARS-CoV2  | Pre-Clinical |  |
| Protein Subunit              | Capsid-like Particle  | AdaptVac (PREVENT-nCoV consortium)  | SARS-CoV2  | Pre-Clinical |  |

**DISCLAIMER:**

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

|                 |  |  |           |              |   |
|-----------------|--|--|-----------|--------------|---|
| Protein Subunit | Drosophila S2 insect cell expression system VLPs                           | ExpreS2ion   | SARS-CoV2 | Pre-Clinical |   |
| Protein Subunit | Peptide antigens formulated in LNP   | IMV Inc  | SARS-CoV2 | Pre-Clinical |   |
| Protein Subunit | S protein  | WRAIR/USAMRIID   | SARS-CoV2 | Pre-Clinical |   |
| Protein Subunit | S protein +Adjuvant  | National Institute of Infectious Disease, Japan                              | SARS-CoV2 | Pre-Clinical | Influenza   |
| Protein Subunit | VLP-recombinant protein + Adjuvant   | Osaka University/ BIKEN/ National Institutes of Biomedical Innovation, Japan | SARS-CoV2 | Pre-Clinical |   |
| Protein Subunit | microneedle arrays S1 subunit  | Univ. of Pittsburgh  | SARS-CoV2 | Pre-Clinical | MERS  |
| Protein Subunit | Peptide  | Vaxil Bio  | SARS-CoV2 | Pre-Clinical |   |
| Protein Subunit | Adjuvanted protein subunit (RBD)   | Biological E Ltd   | SARS-CoV2 | Pre-Clinical |   |
| Protein Subunit | Peptide  | Flow Pharma Inc  | SARS-CoV2 | Pre-Clinical | Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, BreastCA vaccine |
| Protein Subunit | S protein  | AJ Vaccines  | SARS-CoV2 | Pre-Clinical |   |
| Protein Subunit | li-Key peptide   | Generex/EpiVax   | SARS-CoV2 | Pre-Clinical | Influenza, HIV, SARS-CoV  |
| Protein Subunit | S protein  | EpiVax/Univ. of Georgia  | SARS-CoV2 | Pre-Clinical | H7N9  |
| Protein Subunit | Protein Subunit EPV-CoV-19   | EpiVax   | SARS-CoV2 | Pre-Clinical |   |
| Protein Subunit | S protein (baculovirus production)   | Sanofi Pasteur/GSK   | SARS-CoV2 | Pre-Clinical | Influenza, SARS-CoV   |
| Protein Subunit | gp-96 backbone   | Heat Biologics/Univ. Of Miami  | SARS-CoV2 | Pre-Clinical | NSCLC, HIV, malaria, Zika   |
| Protein Subunit | Molecular clamp stabilized Spike protein                                   | University of Queensland/GSK/Dynavax   | SARS-CoV2 | Pre-Clinical | Nipah, influenza, Ebola, Lassa  |
| Protein Subunit | Peptide vaccine  | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo                                | SARS-CoV2 | Pre-Clinical | Ebola   |
| Protein Subunit | Subunit vaccine  | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo                                | SARS-CoV2 | Pre-Clinical |   |
| Protein Subunit | S1 or RBD protein  | Baylor College of Medicine   | SARS-CoV2 | Pre-Clinical | SARS  |
| Protein Subunit | Subunit protein, plant produced  | iBio/CC-Pharming   | SARS-CoV2 | Pre-Clinical |   |
| Protein Subunit | Recombinant protein, nanoparticles (based on S-protein and other epitopes) | Saint-Petersburg scientific research institute of vaccines and serums        | SARS-CoV2 | Pre-Clinical |   |
| Protein Subunit | COVID-19 XWG-03 truncated S (spike) proteins                               | Innovax/Xiamen Univ./GSK   | SARS-CoV2 | Pre-Clinical | HPV   |
| Protein Subunit | Adjuvanted microsphere peptide   | VIDO-InterVac, University of Saskatchewan                                    | SARS-CoV2 | Pre-Clinical |   |
| Protein Subunit | Synthetic Long Peptide Vaccine candidate for S and M proteins              | OncoGen  | SARS-CoV2 | Pre-Clinical |   |
| Protein Subunit | Oral E. coli-based protein expression system of S and N proteins           | MIGAL Galilee Research Institute   | SARS-CoV2 | Pre-Clinical |   |
| Protein Subunit | Nanoparticle vaccine   | LakePharma, Inc.   | SARS-CoV2 | Pre-Clinical |   |

**DISCLAIMER:**

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

|                          |   |   |           |              |                                     |
|--------------------------|---|---|-----------|--------------|-------------------------------------|
| Protein Subunit          | Plant-based subunit (RBD-Fc + Adjuvant)   | Baiya Phytopharm/ Chula Vaccine Research Center                               | SARS-CoV2 | Pre-Clinical |                                     |
| Protein Subunit          | OMV-based vaccine   | Quadram Institute Biosciences   | SARS-CoV2 | Pre-Clinical | Flu A, plague                       |
| Protein Subunit          | OMV-based vaccine   | BiOMViS Srl/Univ. of Trento   | SARS-CoV2 | Pre-Clinical |                                     |
| Protein subunit          | structurally modified spherical particles of the tobacco mosaic virus (TMV)                 | Lomonosov Moscow State University   | SARS-CoV2 | Pre-Clinical | rubella, rotavirus                  |
| Protein Subunit          | Spike-based   | University of Alberta   | SARS-CoV2 | Pre-Clinical | Hepatitis C                         |
| Protein Subunit          | Recombinant S1-Fc fusion protein  | AnyGo Technology  | SARS-CoV2 | Pre-Clinical |                                     |
| Protein Subunit          | Recombinant protein   | Yisheng Biopharma   | SARS-CoV2 | Pre-Clinical |                                     |
| Protein Subunit          | Recombinant S protein in IC-BEVS  | Vabiotech   | SARS-CoV2 | Pre-Clinical |                                     |
| Protein Subunit          | Orally delivered, heat stable subunit   | Applied Biotechnology Institute, Inc.   | SARS-CoV2 | Pre-Clinical |                                     |
| Protein Subunit          | S-2P protein + CpG 1018   | Medigen Vaccine Biologics Corporation/NIAID/Dynavax                           | SARS-CoV2 | Pre-Clinical |                                     |
| Protein Subunit          | Peptides derived from Spike protein   | Axon Neuroscience SE  | SARS-CoV2 | Pre-Clinical |                                     |
| Protein Subunit          | Protein Subunit   | MOGAM Institute for Biomedical Research, GC Pharma                            | SARS-CoV2 | Pre-Clinical |                                     |
| Protein Subunit          | RBD-based   | Neovii/Tel Aviv University  | SARS-CoV2 | Pre-Clinical |                                     |
| Protein Subunit          | RBD-based   | Kentucky Bioprocessing, Inc   | SARS-CoV2 | Pre-Clinical |                                     |
| Protein Subunit          | Outer Membrane Vesicle (OMV)-subunit  | Intravacc/Epivax  | SARS-CoV2 | Pre-Clinical |                                     |
| Protein Subunit          | Outer Membrane Vesicle(OMV)-peptide   | Intravacc/Epivax  | SARS-CoV2 | Pre-Clinical |                                     |
| Protein Subunit          | Spike-based (epitope screening)   | ImmunoPrecise/LiteVax BV  | SARS-CoV2 | Pre-Clinical |                                     |
| Replicating Viral Vector | YF17D Vector  | KU Leuven   | SARS-CoV2 | Pre-Clinical |                                     |
| Replicating Viral Vector | Measles Vector  | Zydus Cadila  | SARS-CoV2 | Pre-Clinical |                                     |
| Replicating Viral Vector | Measles Vector  | Institute Pasteur/Themis/Univ. of Pittsburg Center for Vaccine Research/Merck | SARS-CoV2 | Pre-Clinical | West Nile, Chik, Ebola, Lassa, Zika |
| Replicating Viral Vector | Measles Vector  | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo                                 | SARS-CoV2 | Pre-Clinical |                                     |
| Replicating Viral Vector | Measles Virus (S, N targets)  | DZIF – German Center for Infection Research/CanVirex AG                       | SARS-CoV2 | Pre-clinical | Zika, H7N9, CHIKV                   |
| Replicating Viral Vector | Horsepox vector expressing S protein  | Tonix Pharma/Southern Research  | SARS-CoV2 | Pre-Clinical | Smallpox, monkeypox                 |
| Replicating Viral Vector | Live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)       | BiOCAD and IEM  | SARS-CoV2 | Pre-Clinical | Influenza                           |
| Replicating Viral Vector | Recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal) | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo                                 | SARS-CoV2 | Pre-Clinical | Influenza                           |
| Replicating Viral Vector | Attenuated Influenza expressing an antigenic portion of the Spike protein                   | Fundação Oswaldo Cruz and Instituto Buntantan                                 | SARS-CoV2 | Pre-Clinical | Influenza                           |
| Replicating Viral Vector | Influenza vector expressing RBD   | University of Hong Kong   | SARS-CoV2 | Pre-Clinical |                                     |

**DISCLAIMER:**

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

|                          |   |   |           |              |                       |
|--------------------------|---|---|-----------|--------------|-----------------------|
| Replicating Viral Vector | Replication-competent VSV chimeric virus technology (VSVΔG) delivering the SARS-CoV-2 Spike (S) glycoprotein. | IAVI/Merck  | SARS-CoV2 | Pre-Clinical | Ebola, Marburg, Lassa |
| Replicating Viral Vector | VSV-S   | University of Western Ontario   | SARS-CoV2 | Pre-Clinical | HIV, MERS             |
| Replicating Viral Vector | VSV vector  | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo   | SARS-CoV2 | Pre-Clinical |                       |
| Replicating Viral Vector | VSV-S   | Israel Institute for Biological Research/Weizmann Institute of Science                | SARS-CoV2 | Pre-Clinical |                       |
| Replicating Viral Vector | M2-deficient single replication (M2SR) influenza vector   | UW–Madison/FluGen/Bharat Biotech  | SARS-CoV2 | Pre-Clinical | influenza             |
| Replicating Viral Vector | Newcastle disease virus vector (NDV-SARS-CoV-2/Spike)   | Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.                            | SARS-CoV2 | Pre-Clinical |                       |
| Replicating Viral Vector | Avian paramyxovirus vector (APMV)   | The Lancaster University, UK  | SARS-CoV2 | Pre-Clinical |                       |
| RNA                      | LNP-mRNA  | Translate Bio/Sanofi Pasteur  | SARS-CoV2 | Pre-Clinical |                       |
| RNA                      | LNP-mRNA  | CanSino Biologics/Precision NanoSystems   | SARS-CoV2 | Pre-Clinical |                       |
| RNA                      | LNP-encapsulated mRNA cocktail encoding VLP   | Fudan University/ Shanghai JiaoTong University/RNACure Biopharma                      | SARS-CoV2 | Pre-Clinical |                       |
| RNA                      | LNP-encapsulated mRNA encoding RBD  | Fudan University/ Shanghai JiaoTong University/RNACure Biopharma                      | SARS-CoV2 | Pre-Clinical |                       |
| RNA                      | Replicating Defective SARS-CoV-2 derived RNAs   | Centro Nacional Biotecnología (CNB-CSIC), Spain                                       | SARS-CoV2 | Pre-Clinical |                       |
| RNA                      | LNP-encapsulated mRNA   | University of Tokyo/ Daiichi-Sankyo   | SARS-CoV2 | Pre-Clinical | MERS                  |
| RNA                      | Liposome-encapsulated mRNA  | BIOCAD  | SARS-CoV2 | Pre-Clinical |                       |
| RNA                      | Several mRNA candidates   | RNAimmune, Inc.   | SARS-CoV2 | Pre-Clinical |                       |
| RNA                      | mRNA  | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo   | SARS-CoV2 | Pre-Clinical |                       |
| RNA                      | mRNA  | China CDC/Tongji University/Stermina  | SARS-CoV2 | Pre-Clinical |                       |
| RNA                      | mRNA  | Arcturus/Duke-NUS   | SARS-CoV2 | Pre-Clinical | multiple candidates   |
| RNA                      | LNP-mRNA  | Chula Vaccine Research Center/University of Pennsylvania                              | SARS-CoV2 | Pre-Clinical |                       |
| RNA                      | mRNA in an intranasal delivery system   | eTheRNA   | SARS-CoV2 | Pre-Clinical |                       |
| RNA                      | mRNA  | Greenlight Biosciences  | SARS-CoV2 | Pre-Clinical |                       |
| RNA                      | mRNA  | IDIBAPS-Hospital Clinic, Spain  | SARS-CoV2 | Pre-Clinical |                       |
| VLP                      | Enveloped Virus-Like Particle (eVLP)  | VBI Vaccines Inc.   | SARS-CoV2 | Pre-Clinical |                       |
| VLP                      | S protein integrated in HIV VLPs  | IrsiCaixa AIDS Research/IRTA-CReSA/Barcelona Supercomputing Centre/Grifols            | SARS-CoV2 | Pre-Clinical |                       |
| VLP                      | VLP + Adjuvant  | Mahidol University/ The Government Pharmaceutical Organization (GPO)/Siriraj Hospital | SARS-CoV2 | Pre-Clinical |                       |
| VLP                      | Virus-like particles, lentivirus and baculovirus vehicles   | Navarrabiomed, Oncoimmunology group   | SARS-CoV2 | Pre-Clinical |                       |
| VLP                      | Virus-like particle, based on RBD   | Saiba GmbH  | SARS-CoV2 | Pre-Clinical |                       |

**DISCLAIMER:**

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

|         |                                   |  |                        |              |  |
|---------|-----------------------------------|--|------------------------|--------------|--|
|         | displayed on virus-like particles |  |                        |              |  |
| VLP     | Plant-derived VLP                 | Medicago Inc./ Université Laval                          | SARS-CoV2              | Pre-Clinical | Flu, Rotavirus, Norovirus, West Nile virus, Cancer |
| VLP     | ADDomer™ multiepitope display     | Imophoron Ltd and Bristol University's Max Planck Centre | SARS-CoV2              | Pre-Clinical |  |
| VLP     | Unknown                           | Doherty Institute  | SARS-CoV2              | Pre-Clinical |  |
| VLP     | VLP                               | OSIVAX   | SARS-CoV1<br>SARS-CoV2 | Pre-Clinical |  |
| VLP     | eVLP                              | ARTES Biotechnology                                      | SARS-CoV2              | Pre-Clinical | malaria  |
| VLP     | VLPs peptides/whole virus         | Univ. of Sao Paulo                                       | SARS-CoV2              | Pre-Clinical |  |
| Unknown | Unknown                           | Tulane University  | SARS-CoV2              | Pre-Clinical |  |

**DISCLAIMER:**

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.